Literature DB >> 19464302

Genotype-phenotype correlations in Fanconi anemia.

Kornelia Neveling1, Daniela Endt, Holger Hoehn, Detlev Schindler.   

Abstract

Although still incomplete, we now have a remarkably detailed and nuanced picture of both phenotypic and genotypic components of the FA spectrum. Initially described as a combination of pancytopenia with a limited number of physical anomalies, it was later recognized that additional features were compatible with the FA phenotype, including a form without detectable malformations (Estren-Dameshek variant). The discovery of somatic mosaicism extended the boundaries of the FA phenotype to cases even without any overt hematological manifestations. This clinical heterogeneity was augmented by new conceptualizations. There was the realization of a constant risk for the development of myelodysplasia and certain malignancies, including acute myelogenous leukemia and squamous cell carcinoma, and there was the emergence of a distinctive cellular phenotype. A striking degree of genetic heterogeneity became apparent with the delineation of at least 12 complementation groups and the identification of their underlying genes. Although functional genetic insights have fostered the interpretation of many phenotypic features, surprisingly few stringent genotype-phenotype connections have emerged. In addition to myriad genetic alterations, less predictable influences are likely to modulate the FA phenotype, including modifier genes, environmental factors and chance effects. In reviewing the current status of genotype-phenotype correlations, we arrive at a unifying hypothesis to explain the remarkably wide range of FA phenotypes. Given the large body of evidence that genomic instability is a major underlying mechanism of accelerated ageing phenotypes, we propose that the numerous FA variants can be viewed as differential modulations and compression in time of intrinsic biological ageing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464302     DOI: 10.1016/j.mrfmmm.2009.05.006

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  62 in total

1.  Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.

Authors:  Maria Castella; Roser Pujol; Elsa Callén; Juan P Trujillo; José A Casado; Hans Gille; Francis P Lach; Arleen D Auerbach; Detlev Schindler; Javier Benítez; Beatriz Porto; Teresa Ferro; Arturo Muñoz; Julián Sevilla; Luis Madero; Elena Cela; Cristina Beléndez; Cristina Díaz de Heredia; Teresa Olivé; José Sánchez de Toledo; Isabel Badell; Montserrat Torrent; Jesús Estella; Angeles Dasí; Antonia Rodríguez-Villa; Pedro Gómez; José Barbot; María Tapia; Antonio Molinés; Angela Figuera; Juan A Bueren; Jordi Surrallés
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  Mutations in Fanconi anemia genes and the risk of esophageal cancer.

Authors:  Mohammad R Akbari; Reza Malekzadeh; Pierre Lepage; David Roquis; Ali R Sadjadi; Karim Aghcheli; Abbas Yazdanbod; Ramin Shakeri; Jafar Bashiri; Masoud Sotoudeh; Akram Pourshams; Parviz Ghadirian; Steven A Narod
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

3.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.

Authors:  Raphael Ceccaldi; Kalindi Parmar; Enguerran Mouly; Marc Delord; Jung Min Kim; Marie Regairaz; Marika Pla; Nadia Vasquez; Qing-Shuo Zhang; Corinne Pondarre; Régis Peffault de Latour; Eliane Gluckman; Marina Cavazzana-Calvo; Thierry Leblanc; Jérôme Larghero; Markus Grompe; Gérard Socié; Alan D D'Andrea; Jean Soulier
Journal:  Cell Stem Cell       Date:  2012-06-07       Impact factor: 24.633

Review 4.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

5.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 6.  A role for the base excision repair enzyme NEIL3 in replication-dependent repair of interstrand DNA cross-links derived from psoralen and abasic sites.

Authors:  Zhiyu Yang; Maryam Imani Nejad; Jacqueline Gamboa Varela; Nathan E Price; Yinsheng Wang; Kent S Gates
Journal:  DNA Repair (Amst)       Date:  2017-02-20

Review 7.  Oxidative stress-associated protein tyrosine kinases and phosphatases in Fanconi anemia.

Authors:  Jie Li; Qishen Pang
Journal:  Antioxid Redox Signal       Date:  2014-03-11       Impact factor: 8.401

8.  Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway.

Authors:  Jayabal Panneerselvam; Guoxiang Xie; Raymond Che; Mingming Su; Jun Zhang; Wei Jia; Peiwen Fei
Journal:  J Proteome Res       Date:  2016-03-16       Impact factor: 4.466

9.  Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.

Authors:  Settara C Chandrasekharappa; Francis P Lach; Danielle C Kimble; Aparna Kamat; Jamie K Teer; Frank X Donovan; Elizabeth Flynn; Shurjo K Sen; Supawat Thongthip; Erica Sanborn; Agata Smogorzewska; Arleen D Auerbach; Elaine A Ostrander
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

10.  Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.

Authors:  Andreas Palagyi; Kornelia Neveling; Ursula Plinninger; Andreas Ziesch; Bianca-Sabrina Targosz; Gerald U Denk; Stephanie Ochs; Antonia Rizzani; Daniel Meier; Wolfgang E Thasler; Helmut Hanenberg; Enrico N De Toni; Florian Bassermann; Claus Schäfer; Burkhard Göke; Detlev Schindler; Eike Gallmeier
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.